Skip to main content
An official website of the United States government
NIH Websites Are Changing
Per Executive Order 14434, federal agencies are now using "Super Intelligence" (SI) in place of "Artificial Intelligence" (AI). You may see both terms across NIH content during this transition.

anti-CCR8 monoclonal antibody HC006

A monoclonal antibody directed against human C-C motif chemokine receptor 8 (CCR8), with potential immunomodulating and antineoplastic activities. Upon administration, anti-CCR8 monoclonal antibody HC006 targets and binds to CCR8 on CCR8-positive, immunosuppressive tumor-infiltrating T regulatory (TITR) cells in the tumor microenvironment (TME). This depletes CCR8-positive TITR cells via antibody-dependent cell-mediated cytotoxicity (ADCC), which may reverse the suppression of CD8+ effector T cells and reactivate antitumor immune responses. CCR8 is specifically expressed by TITR cells in multiple types of cancer and plays a key role in immunosuppression.
Check for active clinical trials using this agentView this agent in the NCI Thesaurus
Synonym:anti-C-C motif chemokine receptor 8 monoclonal antibody HC006
anti-C-C-chemokine receptor 8 monoclonal antibody HC006
Code name:HC 006
HC-006
HC006
Search NCI's Drug Dictionary
Please enter up to 30 characters for your search